Top 25 Life Sciences Marketing Agencies in Europe 2026
Europe does not have one life sciences conference circuit but several overlapping ecosystems. Some countries have a clear national gathering where biotechnology companies, investors, researchers, service providers and policymakers meet each year. Germany has the German Biotech Days. Spain has BIOSPAIN. Switzerland has Swiss Biotech Day. Belgium has Knowledge for Growth.
Other countries work differently. The Nordic countries share regional meetings. The Baltic states converge around Life Sciences Baltics. France has a large but fragmented conference landscape without one universally dominant national event. Several smaller markets depend on regional conferences, cluster meetings or international events that happen to be hosted locally.
For commercial teams, this matters. Selecting conferences by reputation alone can lead to an expensive calendar filled with broad international events but few opportunities to build relationships inside the markets that matter most.
This guide maps the main national and regional life sciences conferences across Europe and explains which organisations each event is best suited to.
Research status: Conference information was checked on 25 July 2026. Dates, formats and locations can change, particularly for events that have not yet opened registration.
Europe’s national life sciences conferences at a glance
| Market | Main conference or meeting point | Model | Best suited to |
| Netherlands | Innovation for Health | National ecosystem | Broad life sciences networking |
| Belgium | Knowledge for Growth | National and international | Biotech partnering and ecosystem access |
| Germany | German Biotech Days | National industry forum | German biotech and policy relationships |
| Switzerland | Swiss Biotech Day | National conference with global reach | Partnering, investment and international biotech |
| Spain | BIOSPAIN | National industry event | Partnering and Spanish market access |
| Italy | Meet in Italy for Life Sciences | National ecosystem and brokerage | Partnerships and Italian ecosystem access |
| Austria | Austrian Life Science Day | National thematic meeting | Austrian organisations and public support |
| UK | Genesis | National commercial meeting point | Investment, partnering and UK market access |
| Ireland | BioPharmaChem Impact | National industry summit | Manufacturing, operations and policy |
| Portugal | Biomeet | National biotech meeting | Portuguese biotech networking |
| Greece | BioInnovation Greece Forum | Emerging national forum | Start-ups, investors and ecosystem building |
| Poland | EUROBIOTECH | National and Central European congress | Science, biotech and regional connections |
| Czech Republic | Prague.bio Conference | National and Central European | Start-ups, technology transfer and investors |
| Sweden and Nordics | Nordic Life Science Days | Regional Nordic anchor | Partnering across the Nordic markets |
| Denmark and Nordics | LSX Nordic Congress | Regional investment event | Fundraising and corporate partnering |
| Lithuania, Latvia and Estonia | Life Sciences Baltics | Regional Baltic anchor | Baltic market and innovation access |
| France | No single equivalent | Fragmented national ecosystem | Requires event selection by objective |
Why national conferences deserve a place in a European event strategy
Large international conferences such as BIO-Europe, BIO-Europe Spring and major therapeutic congresses provide scale. They can be highly productive when a company already knows which investors, licensors, partners or customers it wants to meet.
National events perform a different function.
They are often where companies encounter:
- domestic biotechnology associations;
- regional development agencies;
- technology-transfer organisations;
- national investors and grant organisations;
- local pharmaceutical and biotechnology leaders;
- specialist service providers;
- policymakers and cluster representatives;
- companies that rarely attend the largest international meetings.
National conferences can therefore be particularly useful when entering a market, building a local partner network or developing relationships that require repeated contact.
They are generally less useful when a company attends without a geographic priority, defined audience or follow-up plan.
List of national European Life Sciences conferences
→
The Netherlands: Innovation for Health
Innovation for Health is the Netherlands’ broad national meeting point for life sciences and health. The 13th edition was held in Utrecht on 26 March 2026, alongside the Global Investor Forum on 25 March. The event brought together innovators, researchers, investors, policymakers and other organisations from across the Dutch ecosystem.
Why attend Innovation for Health? Innovation for Health is valuable because it covers more than biotechnology alone. The programme and exhibition attract organisations working in pharmaceuticals, biotechnology, medical technology, digital health, research, finance and healthcare innovation.That breadth makes the conference suitable for:
- companies entering the Dutch life sciences market;
- international companies seeking Dutch research or innovation partners;
- service providers building a broad local network;
- early-stage companies looking for investors and ecosystem support;
- Dutch organisations that need visibility beyond their immediate cluster.
The breadth is also its limitation. A company looking only for specialist licensing discussions or a highly specific scientific audience may require a more focused conference.
Best fit: Broad Dutch ecosystem access.
Typical timing: March.
Belgium: Knowledge for Growth
Knowledge for Growth is Belgium’s main life sciences conference and one of Europe’s more internationally visible national ecosystem events. The 2026 edition took place in Antwerp on 3 and 4 June and was positioned around health, biotechnology and cross-sector collaboration.
Why attend Knowledge for Growth? Belgium has concentrated biotechnology and pharmaceutical activity, particularly in Flanders. Knowledge for Growth provides access to that ecosystem while also attracting international companies, investors and service providers.
The event is relevant for:
- biotechnology companies seeking pharmaceutical partners;
- CROs, CDMOs and specialist service providers;
- companies exploring Belgium as an operating or research location;
- investors and technology-transfer teams;
- medtech, healthtech and diagnostics companies;
- organisations seeking collaboration with Belgian clusters and institutions.
The event combines conference content, exhibition presence and business development. Companies generally achieve more when meetings are arranged in advance rather than relying on exhibition traffic alone.
Best fit: Benelux and international biotech business development.
Typical timing: May or June.
Germany: German Biotech Days
The German Biotech Days, or Deutsche Biotechnologietage, are Germany’s national biotechnology forum. The 2026 event was held in Leipzig on 21 and 22 April. BIO Deutschland describes the meeting as Germany’s largest biotechnology event and the national forum for the German biotechnology industry.
Why attend the German Biotech Days? Germany has multiple strong regional clusters, which can make the market difficult to approach through a single location. The German Biotech Days provide one of the few opportunities to meet companies, scientists, investors, funding organisations and policymakers from across the country.It is particularly relevant for:
- companies developing relationships in the German biotechnology industry;
- international service providers entering Germany;
- biotechnology associations and cluster organisations;
- companies that need to understand German funding and policy priorities;
- research organisations seeking commercial partners;
- companies wanting visibility among German biotechnology decision-makers.
The event is more closely connected to the national biotechnology community than many broader international conferences held in Germany.
Best fit: National biotechnology relationships and German market entry.
Typical timing: April.
Switzerland: Swiss Biotech Day
Swiss Biotech Day has developed from a national association meeting into a major international biotechnology conference. The 2026 edition took place in Basel from 4 to 5 May, preceded by a welcome reception, and attracted more than 3,500 participants from 58 countries.
Why attend Swiss Biotech Day? Switzerland combines a mature biotechnology sector with major pharmaceutical companies, specialist service providers, investors and international headquarters.
Swiss Biotech Day is appropriate for:
- biotechnology companies seeking licensing or co-development partners;
- companies raising capital;
- CROs, CDMOs and technology suppliers;
- organisations entering the Swiss market;
- economic development and international trade delegations;
- companies looking for both Swiss and international contacts.
The Global Village and international delegations make the conference more internationally oriented than many other national meetings.
This reach also means competition for attention is considerable. Companies should treat Swiss Biotech Day as a partnering event rather than a general networking day.
Best fit: International biotechnology partnering with strong access to Switzerland.
Typical timing: May.
Spain: BIO Spain
BIOSPAIN is the main conference of the Spanish biotechnology sector. Organised by the Spanish Bioindustry Association, AseBio, the 2026 edition will take place in Bilbao from 29 September to 1 October. The organisers describe BIOSPAIN as one of Europe’s largest events organised by a national bioindustry association, with a substantial international delegation and emphasis on one-to-one meetings.
Why attend BIOSPAIN? BIOSPAIN is one of the clearest choices for companies seeking structured access to a national market.It is suitable for:
- biotechnology companies seeking licensing discussions;
- international companies exploring the Spanish market;
- investors and corporate venture teams;
- diagnostics, medtech and digital-health companies;
- CROs, CDMOs and scientific service providers;
- regional clusters and economic-development organisations.
The rotating host location can expose attendees to different Spanish regional ecosystems. The partnering programme makes the event particularly useful for teams that define targets before registering.
Best fit: Structured partnering and access to Spanish biotechnology.
2026 date: 29 September–1 October.
Italy: Meet in Italy for Life Sciences
Meet in Italy for Life Sciences, frequently shortened to MIT4LS, is Italy’s main cross-sector life sciences meeting. The 2026 edition will take place in Rome on 13 and 14 October and includes a brokerage programme for pre-arranged meetings. The event brings together research, industry, healthcare organisations, public institutions, investors and innovation ecosystems.
Why attend Meet in Italy for Life Sciences? Italy’s life sciences sector is geographically distributed, with strong pharmaceutical, medical-device, diagnostics, biotechnology and research capabilities in several regions.
MIT4LS is most relevant for:
- organisations seeking Italian research and commercial partners;
- companies looking for distributors or local collaborators;
- service providers entering Italy;
- start-ups and academic spin-outs;
- technology-transfer organisations;
- investors evaluating Italian opportunities.
The brokerage component should be the centre of an attendee’s planning. Simply exhibiting without a prepared meeting schedule may deliver limited results.
Best fit: Partner discovery across Italy’s distributed ecosystem.
2026 date: 13–14 October.
Austria: Austrian Life Science Day
The Austrian Life Science Day is organised through Austria’s national life sciences network. The fourth edition took place in Vienna on 16 June 2026 and focused on clinical evidence for drugs and medical devices, alongside funding and partnering opportunities.
Why attend Austrian Life Science Day? This is a smaller and more targeted event than Swiss Biotech Day or BIOSPAIN. Its value lies in access to Austria’s national network, public support organisations and local companies.
It is suitable for:
- companies with a specific Austrian market interest;
- organisations seeking Austrian research or development partners;
- drug and medical-device developers;
- start-ups evaluating funding opportunities;
- specialist consultants and service providers;
- companies already active in Central Europe.
The thematic focus can vary by edition, so companies should assess the programme before making it a recurring calendar commitment.
Best fit: Focused access to Austria’s life sciences support network.
Typical timing: June.
United Kingdom: Genesis
The UK has many strong regional and specialist events, but Genesis, organised by One Nucleus, is one of the most established commercial meeting points. Genesis 2026 is scheduled for 10 December in London and will bring together investors, innovators, industry leaders and service providers through conference sessions, showcases and partnering.
Why attend Genesis? Genesis is most useful for commercial and strategic conversations rather than large-scale exhibition visibility.
Relevant attendees include:
- UK and European biotechnology executives;
- investors and corporate business development teams;
- early-stage and growth-stage companies;
- technology-transfer organisations;
- life sciences advisers and service providers;
- companies entering the UK market.
The UK ecosystem is too large to be represented by one meeting. Companies may also need regional events in Cambridge, Oxford, London, Scotland or the North of England, depending on their target audience.
Best fit: UK investment, commercial strategy and partnering.
2026 date: 10 December.
Ireland: BioPharmaChem Impact
BioPharmaChem Impact is a senior industry summit organised with BioPharmaChem Ireland, Enterprise Ireland and IDA Ireland. The 2026 conference attracted approximately 430 delegates and focused heavily on manufacturing, biologics, active pharmaceutical ingredients, operational resilience and industrial policy.
Why attend BioPharmaChem Impact? Ireland’s ecosystem includes substantial pharmaceutical and biopharmaceutical manufacturing. The conference therefore differs from start-up and investor-dominated biotechnology meetings.
It is most relevant for:
- pharmaceutical and biopharmaceutical manufacturers;
- engineering, automation and manufacturing-technology providers;
- CDMOs and supply-chain organisations;
- quality, regulatory and operational specialists;
- companies evaluating investment or expansion in Ireland;
- senior industry and government stakeholders.
Discovery-stage biotechnology companies seeking investors may find other meetings more suitable unless they have manufacturing, scale-up or Irish expansion objectives.
Best fit: Biopharmaceutical manufacturing and senior industry relationships.
Typical timing: Spring.
Portugal: Biomeet
Biomeet is described by P-BIO as the annual meeting of the Portuguese biotechnology sector. The event is designed for national and international stakeholders and combines biotechnology content with networking and partnership development.
Portugal also hosted BIO-Europe Spring in Lisbon in March 2026, giving the national ecosystem unusual international exposure that year.
Why attend Biomeet? Biomeet is appropriate for companies whose objective is specifically to understand or enter the Portuguese biotechnology ecosystem.
Potential attendees include:
- international biotechnology companies;
- Portuguese start-ups and scale-ups;
- investors and accelerators;
- academic and translational organisations;
- technology and service providers;
- companies seeking Iberian partnerships.
For broader European partnering, BIO-Europe Spring may deliver more scale. For sustained Portuguese market development, Biomeet can offer better local concentration.
Best fit: Direct access to the Portuguese biotechnology community.
Greece: BioInnovation Greece Forum
The BioInnovation Greece Forum is emerging as a national meeting point for the Greek biotechnology ecosystem. The 2026 forum is scheduled for 1–4 October in Athens and aims to connect biotechnology, healthcare, research, start-ups, investors and public policy, including members of the Greek scientific diaspora.
Why attend BioInnovation Greece Forum? Greece does not yet have the same mature national conference infrastructure as Germany, Switzerland or Spain. This makes the forum potentially valuable for organisations interested in an ecosystem at an earlier stage of commercial consolidation.It may suit:
- investors seeking emerging opportunities;
- start-ups and academic spin-outs;
- international organisations looking for Greek research connections;
- companies interested in health innovation and entrepreneurship;
- diaspora professionals and industry builders.
The conference should currently be considered an ecosystem-development event rather than a direct substitute for a major European partnering conference.
Best fit: Early access to Greece’s developing biotechnology network.
2026 date: 1–4 October.
Poland: EUROBIOTECH
The Central European Congress of Life Sciences EUROBIOTECH is held in Kraków and combines scientific, biotechnology and commercial themes. The tenth edition took place on 2 and 3 July 2026.
Why attend EUROBIOTECH? EUROBIOTECH has a stronger scientific and academic orientation than some national industry association conferences, but it also provides access to Polish and Central European organisations.
It is suited to:
- research-led biotechnology companies;
- academic and translational scientists;
- technology providers;
- organisations seeking Polish collaborators;
- companies exploring Central and Eastern Europe;
- life sciences suppliers with a scientific audience.
Companies focused exclusively on investor partnering should review the delegate composition carefully.
Best fit: Scientific-commercial relationships in Poland and Central Europe.
Typical timing: June or July.
Czech Republic: Prague.bio Conference
The Prague.bio Conference has become a visible meeting for Czech and Central European biotechnology start-ups, investors, researchers and industry organisations. The 2026 event is scheduled for 23 September and expects more than 400 participants, with pitches, investor discussions, panels and partnering.
Why attend Prague.bio? Prague.bio is particularly useful for companies interested in early-stage innovation and technology transfer.
It is relevant for:
- biotechnology founders;
- early-stage investors;
- academic spin-outs;
- research commercialisation teams;
- pharmaceutical scouts;
- specialist service providers working with start-ups.
The conference’s Central European positioning means it may produce contacts beyond the Czech Republic, although its scale remains more focused than BIOSPAIN or Swiss Biotech Day.
Best fit: Central European start-ups, investors and translational science.
2026 date: 23 September.
The Nordic countries: Nordic Life Science Days
The Nordic markets increasingly operate as a regional ecosystem rather than five separate national conference circuits.
Nordic Life Science Days, organised by SwedenBIO, is the main regional anchor. The 2026 edition will take place in Stockholm on 8 and 9 September and combines conference programming, partnering, workshops and Nordic company visibility.
Which countries does Nordic Life Science Days cover?
The event is particularly relevant for:
- Sweden;
- Denmark;
- Norway;
- Finland;
- Iceland;
Companies should not assume that one Nordic meeting replaces all national activity. Denmark’s pharmaceutical ecosystem, Sweden’s biotech and medtech clusters, Finland’s health technology strengths and Norway’s specialist communities still require targeted follow-up.
LSX Nordic Congress as an alternative
The LSX Nordic Congress in Copenhagen is more explicitly focused on investment, corporate development and partnering. The 2026 edition took place on 19 and 20 May.
Choose Nordic Life Science Days for broader regional ecosystem access. Choose LSX Nordic Congress when fundraising, investment or senior corporate partnering is the dominant objective.
Best fit: Regional Nordic business development.
The Baltic states: Life Sciences Baltics
Lithuania, Latvia and Estonia are usually better approached as a regional Baltic ecosystem than through three separate national conferences.
Life Sciences Baltics is positioned as the leading regional meeting for biotechnology, pharmaceuticals, medical devices and health technology. The next edition is scheduled for Vilnius in April 2027 rather than 2026.
Why attend Life Sciences Baltics? The event is most relevant for:- companies exploring the Lithuanian, Latvian and Estonian markets;
- start-ups and innovation organisations;
- international investors;
- digital-health and medtech companies;
- biotechnology and diagnostics businesses;
- economic-development and cluster representatives.
Because the event is not annual, commercial teams should combine it with national cluster activities and targeted visits during intervening years.
Best fit: Consolidated access to the Baltic life sciences ecosystem.
France: a major ecosystem without one obvious national equivalent
France is one of Europe’s largest life sciences markets, yet it does not have a single conference that plays exactly the same role as BIOSPAIN, the German Biotech Days or Swiss Biotech Day.
The France Biotech calendar contains national, regional and specialist meetings covering biotechnology, pharmaceuticals, financing, therapeutic development and international business.
This means companies should choose French events according to their objective:
- Fundraising: investor and venture conferences.
- Drug development: therapeutic or platform-specific meetings.
- Regional access: cluster meetings in Paris, Lyon, Strasbourg, Nantes and other hubs.
- Market entry: France Biotech, Business France and regional ecosystem events.
- Pharmaceutical relationships: larger European partnering meetings and targeted corporate outreach.
France demonstrates why a conference strategy cannot simply assign one event to every country. In fragmented but mature markets, a combination of specialist events and direct outreach may outperform one general conference.
What about the rest of Europe?
Not every European country currently has a large, internationally visible national life sciences conference.
In several markets, the main meeting point is one of the following:
- a biotechnology association’s annual meeting;
- a university or science-park conference;
- a start-up and investor event;
- a pharmaceutical manufacturing exhibition;
- a regional cluster meeting;
- a healthcare innovation conference;
- a neighbouring country’s regional event.
This pattern is common in:
- Romania;
- Bulgaria;
- Croatia;
- Slovenia;
- Slovakia;
- Hungary;
- Luxembourg;
- Cyprus;
- Malta;
- Iceland;
- the Western Balkans.
That does not mean these countries lack relevant life sciences activity. It means the ecosystem is not concentrated in one conference with sufficient cross-sector attendance to act as a national commercial anchor.
For these markets, companies should begin with national biotechnology associations, investment agencies, clusters, science parks and known local partners rather than selecting an event from a generic conference directory.
How should a life sciences company choose between European conferences?
The best conference is not necessarily the largest event. It is the event with the highest concentration of organisations relevant to the company’s current commercial objective.
Use these five criteria.
1. Geographic priority
Choose a national event when the company genuinely wants to build activity in that country.
A Dutch CRO attending BIOSPAIN should have a reason to develop Spanish relationships. Without that priority, a broader European partnering event may be more efficient.
2. Audience concentration
Review whether the conference primarily attracts:
- investors;
- pharmaceutical business development;
- biotechnology founders;
- researchers;
- manufacturers;
- service providers;
- policymakers;
- healthcare organisations.
An event with 400 highly relevant participants can outperform an exhibition with several thousand broad visitors.
3. Meeting structure
Conferences with formal partnering platforms reward early preparation. General ecosystem events depend more heavily on invitations, side meetings and existing relationships.
The event format should match the team’s business development capability.
4. Company stage
| Company situation | Event type to prioritise |
| Pre-seed or university spin-out | Investor, start-up and technology-transfer meetings |
| Fundraising biotech | Investor and structured partnering conferences |
| Clinical-stage biotech | Pharmaceutical partnering and specialist congresses |
| CRO or CDMO | National ecosystem events and targeted development conferences |
| Medtech company | Mixed life sciences and healthcare innovation events |
| International market entrant | National conferences, trade bodies and cluster meetings |
| Established pharmaceutical company | Specialist congresses, policy events and partnering conferences |
5. Ability to activate the conference
Do not attend unless the company can support:
- a defined target list;
- pre-event outreach;
- clear positioning;
- prepared meeting materials;
- daily follow-up;
- post-conference relationship management.
Conference performance usually depends more on preparation and follow-up than on booth size.
Common conference-planning mistakes for conferences
Choosing events because competitors attend
Competitor attendance does not demonstrate that the event serves the same commercial objective.
Treating exhibition presence as a strategy
A booth provides a meeting location. It does not create demand or replace targeted outreach.
Starting outreach two weeks before the event
Investor, pharmaceutical and senior business development diaries often fill well before the conference begins.
Sending the wrong team
A scientific conference may require technical leadership. A partnering conference may require a chief business officer or founder who can make commitments.
Measuring badge scans instead of commercial progress
Useful measures include:
- target organisations engaged;
- qualified conversations;
- follow-up meetings secured;
- opportunities created;
- existing relationships advanced;
- market intelligence collected.
Failing to follow up
A conference conversation is rarely an opportunity by itself. It becomes commercially meaningful through timely, relevant follow-up.
Frequently Asked Questions
What is the largest national biotechnology conference in Europe?
Swiss Biotech Day and BIOSPAIN are among the most internationally visible conferences organised around national biotechnology ecosystems. Swiss Biotech Day reported more than 3,500 attendees from 58 countries in 2026, while BIOSPAIN is one of Europe’s largest meetings organised by a national bioindustry association.
Which European life sciences conference is best for partnering?
The answer depends on the target market. Swiss Biotech Day and BIOSPAIN provide substantial international partnering, while Knowledge for Growth is particularly useful for the Belgian and Benelux ecosystem. Nordic Life Science Days is the main regional choice for the Nordic markets.
Are national life sciences conferences better than BIO-Europe?
They serve different purposes. BIO-Europe provides international scale and a large formal partnering environment. National conferences offer deeper access to domestic companies, clusters, investors and institutions. Many companies benefit from attending both, provided each event has a separate role.
Which conference should a CRO or CDMO attend?
CROs and CDMOs should prioritise conferences with a strong concentration of biotechnology and pharmaceutical decision-makers rather than general scientific audiences. Knowledge for Growth, Swiss Biotech Day, BIOSPAIN, the German Biotech Days and Nordic Life Science Days may be relevant, depending on geographic priorities and service focus.
How early should conference planning begin?
Major partnering events should normally enter the commercial plan several months in advance. Target selection, messaging and outreach should begin before partnering diaries become crowded. Exhibition design should follow the commercial plan, not lead it.
Does every European country have a national life sciences conference?
No. Several countries have a recognised national meeting, while others depend on regional events, specialist meetings or cluster activities. The Nordic and Baltic markets are prominent examples of regional conference models.
Choose markets before choosing conferences
Europe offers a dense life sciences conference calendar, but more events do not automatically create more commercial opportunities.
Start with the countries, organisations and relationships the company wants to develop. Then select conferences that concentrate those audiences and provide an appropriate meeting format.
Innovation for Health, Knowledge for Growth, the German Biotech Days, Swiss Biotech Day, BIOSPAIN and other national events can all be productive. Their value depends on whether the event supports a defined market objective and whether the company has a plan to convert attendance into continued conversations.
Planning your European life sciences conference calendar? Contact JPP to connect event selection, outreach, content and follow-up to one commercial strategy.
How to plan conference activity with JPP
JPP helps life sciences companies connect conference attendance to a broader commercial strategy.
That can include:
- selecting conferences around priority markets and audiences;
- developing target-account lists;
- clarifying the value proposition;
- planning pre-event outreach;
- creating conference campaigns and content;
- arranging and preparing meetings;
- supporting on-site business development;
- managing follow-up and pipeline progression;
- assessing conference performance.
The objective is not to fill the calendar. It is to create a manageable conference programme in which every event has a defined commercial role.